Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating older patients with diffuse large B-cell lymphoma.
Key facts
- Study ID
- NCT00101010
- Run by
- M.D. Anderson Cancer Center
- People needed
- 80
- Starts
- 2005-09-01
- Expected to finish
- 2014-09-01
- Last updated by the study team
- 2020-10-19
Who can join
Age: 61 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center — Fort Smith, Arkansas, United States
- CCOP - Grand Rapids — Grand Rapids, Michigan, United States
- CCOP - Kalamazoo — Kalamazoo, Michigan, United States
- Cancer Research for the Ozarks — Springfield, Missouri, United States
- Hematology Oncology Associates of Central New York, PC - Northeast Center — East Syracuse, New York, United States
- CCOP - Upstate Carolina — Spartanburg, South Carolina, United States
- University of Texas M.D. Anderson CCOP Research Base — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.